A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee
- Author
- PACURARIU, Alexandra C1 2 ; COLOMA, Preciosa M1 ; VAN HAREN, Anja2 ; GENOV, Georgy3 ; STURKENBOOM, Miriam C. J. M1 ; STRAUS, Sabine M. J. M1
[1] Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, Netherlands
[2] Dutch Medicines Evaluation Board, Utrecht, Netherlands
[3] European Medicines Agency, London, United Kingdom - Source
Drug safety. 2014, Vol 37, Num 12, pp 1059-1066, 8 p ; ref : 22 ref
- ISSN
- 0114-5916
- Scientific domain
- Pharmacology drugs; Toxicology
- Publisher
- Adis International, Auckland
- Publication country
- New Zealand
- Document type
- Article
- Language
- English
- Keyword (fr)
- Détection signal Efficacité traitement Evaluation Facteur risque Gestion risque Notification spontanée Organisation système Pharmacovigilance Agence européenne du médicament Comité pour lévaluation des risques en matière de pharmacovigilance
- Keyword (en)
- Signal detection Treatment efficiency Evaluation Risk factor Risk management Spontaneous notification System configuration Pharmacovigilance
- Keyword (es)
- Detección señal Eficacia tratamiento Evaluación Factor riesgo Gestión riesgo Notificación espontánea Organización sistema Farmacovigilancia
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A06 Clinical trial. Drug monitoring
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 29089379
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s40264-014-0240-1 
https://dx.doi.org/10.1007/s40264-014-0240-1
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s40264-014-0240-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Drug safety\";s:9:\"\u0000*\u0000stitle\";s:8:\"Drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"37\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1059\";s:8:\"\u0000*\u0000epage\";s:4:\"1066\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0114-5916\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"PACURARIU\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Alexandra C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"COLOMA, Preciosa M\";i:1;s:15:\"VAN HAREN, Anja\";i:2;s:13:\"GENOV, Georgy\";i:3;s:27:\"STURKENBOOM, Miriam C. J. M\";i:4;s:22:\"STRAUS, Sabine M. J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s40264-014-0240-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Drug safety\";s:9:\"\u0000*\u0000stitle\";s:8:\"Drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"37\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1059\";s:8:\"\u0000*\u0000epage\";s:4:\"1066\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0114-5916\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"PACURARIU\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Alexandra C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"COLOMA, Preciosa M\";i:1;s:15:\"VAN HAREN, Anja\";i:2;s:13:\"GENOV, Georgy\";i:3;s:27:\"STURKENBOOM, Miriam C. J. M\";i:4;s:22:\"STRAUS, Sabine M. J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s40264-014-0240-1\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s40264-014-0240-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Drug safety\";s:9:\"\u0000*\u0000stitle\";s:8:\"Drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"37\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1059\";s:8:\"\u0000*\u0000epage\";s:4:\"1066\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0114-5916\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"PACURARIU\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Alexandra C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"COLOMA, Preciosa M\";i:1;s:15:\"VAN HAREN, Anja\";i:2;s:13:\"GENOV, Georgy\";i:3;s:27:\"STURKENBOOM, Miriam C. J. M\";i:4;s:22:\"STRAUS, Sabine M. J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s40264-014-0240-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Drug safety\";s:9:\"\u0000*\u0000stitle\";s:8:\"Drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"37\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1059\";s:8:\"\u0000*\u0000epage\";s:4:\"1066\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0114-5916\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"PACURARIU\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Alexandra C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"COLOMA, Preciosa M\";i:1;s:15:\"VAN HAREN, Anja\";i:2;s:13:\"GENOV, Georgy\";i:3;s:27:\"STURKENBOOM, Miriam C. J. M\";i:4;s:22:\"STRAUS, Sabine M. J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s40264-014-0240-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Drug safety\";s:9:\"\u0000*\u0000stitle\";s:8:\"Drug saf\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"37\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1059\";s:8:\"\u0000*\u0000epage\";s:4:\"1066\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0114-5916\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"PACURARIU\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Alexandra C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"COLOMA, Preciosa M\";i:1;s:15:\"VAN HAREN, Anja\";i:2;s:13:\"GENOV, Georgy\";i:3;s:27:\"STURKENBOOM, Miriam C. J. M\";i:4;s:22:\"STRAUS, Sabine M. J. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
